Patients with haemophilia often require analgesics due to haemophilic arthropathy.
Advantage of coxibs over ns-NSAIDs is the reduced risk of GI bleedings.
FVIII or FXI deficiency does not protect from atherosclerosis nor atherothrombosis.
Coxibs may increase the cardiovascular risk in patients with haemophilia.
Coxibs should be used with caution in patients with haemophilia.